Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Daily

Download Data

Icosavax Inc Enterprise Value (EV) on February 29, 2024

Icosavax Inc Enterprise Value (EV) is NA on February 29, 2024, a NA change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.

Icosavax Inc 52-week high Enterprise Value (EV) is NA on February 29, 2024, which is NA below the current Enterprise Value (EV).
Icosavax Inc 52-week low Enterprise Value (EV) is NA on February 29, 2024, which is NA below the current Enterprise Value (EV).
Icosavax Inc average Enterprise Value (EV) for the last 52 weeks is NA.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends